TY - JOUR
T1 - The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice
AU - Aizman, Elizabeta
AU - Mor, Adi
AU - Chapman, Joab
AU - Assaf, Yaniv
AU - Kloog, Yoel
N1 - Funding Information:
This work was supported in part by The Israel Science Foundation 912/06 (Y. Kloog) and by the Prajs-Drimmer Institute for The Development of Anti-degenerative Drugs (E-A and A-M). Y. Kloog is the incumbent of the Jack H. Skirball Chair in Applied Neurobiology and head of Prajs-Drimmer Institute.
PY - 2010/12/15
Y1 - 2010/12/15
N2 - EAE is a common animal model for multiple sclerosis (MS). Immunomodulatory treatments such as glatiramer acetate (GA, Copaxone) are beneficial in EAE but are not universally effective in the clinic. The Ras inhibitor farnesylthiosalycylic acid (FTS, Salirasib), efficiently ameliorate EAE as well. Here we demonstrate a synergistic beneficial effect of the combined GA and FTS treatment on EAE; 22.5% of the combined-treatment mice developed disease compared to 87.5%, 77.5% and 82.5% of mice treated with vehicle, GA and FTS, respectively, results supported by MRI, histological, immunological and biochemical data. Such a combined treatment may improve clinical outcome in MS patients.
AB - EAE is a common animal model for multiple sclerosis (MS). Immunomodulatory treatments such as glatiramer acetate (GA, Copaxone) are beneficial in EAE but are not universally effective in the clinic. The Ras inhibitor farnesylthiosalycylic acid (FTS, Salirasib), efficiently ameliorate EAE as well. Here we demonstrate a synergistic beneficial effect of the combined GA and FTS treatment on EAE; 22.5% of the combined-treatment mice developed disease compared to 87.5%, 77.5% and 82.5% of mice treated with vehicle, GA and FTS, respectively, results supported by MRI, histological, immunological and biochemical data. Such a combined treatment may improve clinical outcome in MS patients.
KW - Experimental autoimmune encephalomyelitis
KW - FTS
KW - Farnesylthiosalycylic acid
KW - Glatiramer acetate
KW - Multiple sclerosis
KW - Salirasib
UR - http://www.scopus.com/inward/record.url?scp=78650205270&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2010.08.022
DO - 10.1016/j.jneuroim.2010.08.022
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:78650205270
SN - 0165-5728
VL - 229
SP - 192
EP - 203
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
IS - 1-2
ER -
